登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C56H106O13
化学文摘社编号:
分子量:
987.43
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
产品名称
22:0 Trehalose, Avanti Research™ - A Croda Brand
InChI key
ZLJJDBSDZSZVTF-LXOQPCSCSA-N
SMILES string
O[C@H]([C@@H](COC(CCCCCCCCCCCCCCCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)COC(CCCCCCCCCCCCCCCCCCCCC)=O)[C@@H]1O)[C@@H]2O)[C@@H]2O
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (890808P-25mg)
pkg of 1 × 5 mg (890808P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
Application
22:0 Trehalose has been used as an adjuvant for Chlamydia vaccine. It has also been used as a component in adjuvant DMT (dimethyldioctadecylammonium/monophosphoryl lipid A/trehalose 6,6′-dibehenate (DDA/MPL/TDB)) to prepare DMT liposome adjuvanted CTT3H (polyprotein) vaccine.
Biochem/physiol Actions
Incorporation of trehalose 6,6′-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets. It acts as an immunomodulator. 22:0 Trehalose is considered less toxic and an efficient vaccine adjuvant for tuberculosis.
General description
22:0 Trehalose is a bioactive glycolipid and an analog of mycobacterial cord factor.
Other Notes
For R&D use only. Not for drug, household, or other uses.
Packaging
5 mL Amber Glass Screw Cap Vial (890808P-25mg)
5 mL Amber Glass Screw Cap Vial (890808P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Xindong Teng et al.
Human vaccines & immunotherapeutics, 11(6), 1456-1464 (2015-04-24)
Different strategies have been proposed for the development of protein subunit vaccine candidates for tuberculosis (TB), which shows better safety than other types of candidates and the currently used Bacillus Calmette-Guérin (BCG) vaccine. In order to develop more effective protein
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持